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doi:10.1016/j.ejvs.2009.03.004Abstract Objective: To report the long-term results of stenting for chronic ilio-caval obstruc-
tive lesions.
Material and methods: FromJanuary1996 toJanuary2008, 89patients (72women,17men;median
age 43 years) were admitted for endovascular treatment of chronic disabling non-malignant obstruc-
tive ilio-caval lesions. PatientswereclassifiedasC2 in 15 cases,C3 in 59,C4 in seven,C5 in twoandC6
in six. Median preoperative venous disability score (VDS) and venous clinical severity score (VCSS)
were 2 and 9, respectively. Aetiology was primary in 52 patients, secondary in 35 and congenital in
two. Lesions were bilateral in seven cases, eight patients had inferior vena cava (IVC) involvement
and18hadcommonfemoral vein (CFV)obstructive lesions.Completeocclusionwas found in30cases.
Results: Technical success was achieved in 98%. The median hospital stay was 2 days. During
a median follow-up of 38 months (range: 1e144 months), one patient died and five cases of
thromboses occurred. Iterative stenting was performed for restenosis in six cases. Primary, as-
sisted-primary and secondary patency rates, in terms of intention to treat, were 83%, 89% and
93%, respectively, at 3 and 10 years, with a median VDS of 1. Univariate analysis found that
significant factors affecting patency were CFV involvement for primary patency and history
of deep venous thrombosis (DVT) and CFV involvement for secondary patency.
The last 46 patients had statistically more severe lesions than the first 43 (higher VDS, more
secondary lesions, more occlusions, more stented segments, higher length of stented vein),
and in spite of which patency rates are not different.
Conclusion: Endovenous angioplasty, combined with stenting, is a sure, safe, effective and
very minimally invasive technique which provides good long-term patency rates. Currently,
it is recognised as the technique of choice for the treatment of ilio-caval obstructive lesions.
Surgery should be proposed only in case of failure.
ª 2009 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.MD, Service de Chirurgie Vasculaire, CHU Nord, Chemin des Bourrelly, 13915 Marseille Cedex 20,
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Endovascular Management: Stenting of Chronic Ilio-caval Lesions 119Obstructive venous lesions represent a therapeutic chal- Table 1 Patients’ data.All
patients
>4
years
<4
years
p
N 89 43 46
Median age 43 42 45 0.5322
Female/male ratio 4.2 5.1 3.6 0.512
History of DVT/PE 44 (49%) 18 (42%) 26 (56%) 0.166
Clinical status
Symptomatic 100% 100% 100%
Bilateral symptoms 15 (17%) 9 (21%) 6 (13%) 0.320
C2 15 (17%) 8 (19%) 7 (15%)
C3 59 (66%) 29 (68%) 30 (65%)
C4 7 (8%) 4 (9%) 3 (7%) 0.621
C5 2 (2%) 1 (2%) 1 (2%)
C6 6 (7%) 1 (2%) 5 (11%)
Venous claudication 45 (51%) 18 (42%) 27 (59%) 0.112lenge. Until the mid-1990s, they were treated medically or
were proposed for surgical treatment. In a randomised
prospective trial on patients with acute ilio-femoral deep
venous thrombosis (DVT), Plate demonstrated that anti-
coagulation treatment does not protect against the onset of
post-thrombotic disease and that 59% of patients had
severe obstructive iliac lesions.1 Different surgical tech-
niques (such as Palma procedure and axial bypass) were
used to treat them depending on the extent of the lesions.
There are few reports with populations of more than 10
patients. Results were very variable and long-term patency
was ranging between 44% and 85%.2 Endovenous angio-
plasty, combined with stenting, has emerged as the method
of choice for the treatment of ilio-caval obstructive
lesions.3e5 The goal of this study is to report our experience
and to analyse the long-term results of stenting for chronic
ilio-caval obstructive lesions.PCS 26 (29%) 9 (21%) 17 (37%) 0.096
Median VDS 2 2 3 0.000331
Median VCSS 9 9 9 0.3787
Aetiology
EP 52 (59%) 30 (70%) 22 (48%)
ES 35 (39%) 11 (25%) 24 (52%) 0.01290
EC 2 (2%) 2 (5%) 0
Anatomic lesions
Left side only 79 (89%) 38 (89%) 41 (89%)
Right side only 2 (2%) 1 (2%) 1 (2%)
Bilateralþ IVC 7 (8%) 4 (9%) 3 (7%) 0.9242
IVC only 1 (1%) 0 1 (2%)
CFV 18 (20%) 6 (14%) 12 (26%) 0.154
N segment 140 60 80 0.106
Occlusion 30 (34%) 10 (23%) 20 (44%) 0.043
DVTPE: Deep venous thrombosis; PE: pulmonary embolism; PCS:
pelvic congestion syndrome; VDS: venous disability score; VCSS:
venous clinical severity score; IVC: inferior vena cava; CVF:
common femoral vein; RPF: retroperitoneal fibrosis.Material and Methods
From January 1996 to January 2008, 89 patients were
admitted (intention to treat) to our department for endo-
vascular treatment of chronic symptomatic disabling non-
malignant obstructive ilio-caval lesions. All patients
remained disabled despite previous medical therapy,
including compressive elastic stockings in all cases. Patients
were not considered for endovascular approach if their life
expectancy was limited to less than 5 years (malignant
disease, severe chronic obstructive pulmonary disease,
cardiac failure with forced expiratory volume (FEV) <35%
and severe coronary disease). For treating chronic disease,
no stenting was performed in pregnant patients.
There were 72 women and 17 men (femaleemale ratio,
approximately 4:2) and their median age was 43 years
(ranging from 16 to 79 years). They can be divided into two
groups according to the date of treatment: 43 were treated
more than 4 years earlier and 46 less than 4 years earlier
(Table 1). Of the 72 women, 58 had a history of pregnancy
with a median of two pregnancies per woman (ranging from
1 to 8). Eighteen patients had a history of varicose surgery,
six of hysterectomy, two of urological procedures for
retroperitoneal fibrosis, four of renal insufficiency
(including one under haemodialysis), three of pelvic
radiotherapy and one each of pelvic fracture and hepa-
tectomy for hydatid cyst.
Moreover, 44 had previous DVT, including one portal vein
thrombosis and 10 of whom also had a history of pulmonary
embolism. Three of these patients had interventional therapy:
one isolated in situ thrombolysisandtwovenous thrombectomy
with inferior vena cava (IVC) clip insertion (including one after
failure of thrombolysis). Testing for thrombophylia was per-
formed in all patients who had previous DVT. It revealed four
cases of factor V mutation, one case of factor II mutation, five
cases of increased factor VIII, three deficit of S protein, one
deficit of factor XII and threecases of hyperhomocysteinaemia.
Moreover, one patient had autoimmune thrombocytopenia and
one had platelet hyperaggregability.
All patients were symptomatic. According to the CEAP
clinical classification,6 patients were classified as C2S in 15
cases, C3S in 59, C4S in seven, C5S in two and C6S in six. Mostof the patients (NZ 72) had left unilateral symptoms but
the symptoms were bilateral in 15 cases and were located
on the right side only in two cases. Forty-five patients had
venous claudication. Moreover, 26 women suffered from
pelvic congestion syndrome (patients suffering from iso-
lated pelvic congestion syndrome (NZ 14) were classified
as C2), including five who had previous embolisation of
pelvic varices (MayeThurner syndrome was not identified at
this time). Median preoperative venous disability score
(VDS) and venous clinical severity score (VCSS)7 were 2
(range: 2e3) and 9 (range: 4e25), respectively.
All patients had preoperative colour Doppler ultraso-
nography of the lower extremities and pelvis and computed
tomographic venography or magnetic resonance venog-
raphy. Currently, preoperative phlebography or iliocavog-
raphy is performed only in complex cases.
According to the CEAP aetiological classification,6 52
were classified as primary (EP, MayeThurner syndrome), 35
secondary (ES, post-thrombotic disease in 30 cases and
retroperitoneal fibrosis in five cases) and two congenital
(EC). Venous lesions were located on the left side in 79
cases, on the right side in only two cases, while the lesions
120 O. Hartung et al.were bilateral in seven cases and in one case an isolated IVC
lesion (from the infrarenal portion to the ostia of the
suprahepatic veins) was present. The IVC was involved in
eight cases and the common femoral vein in 18 cases (all
post-thrombotic lesions). In all, 140 ilio-caval segments
were involved (one to five per patient). Thirty patients had
at least one totally occluded ilio-caval venous segment (23
of post-thrombotic aetiology).
All procedures were performed in the operating room.
After percutaneous venous access, an iliocavography was
performed through a 5Fr sheath (Figs. 1A and 2A). If there
was venous segment(s) occlusion, re-canalisation was per-
formed using a 0.035 hydrophylic guidewire and a vertebral
angiographic catheter (Fig. 2B). Then a larger sheath (9F in
most of the cases) was inserted and unfractionated heparin
50 UI kg1, 500 mg of aspirin and cefamandole for infection
prophylaxis were given intravenously. Balloon angioplasty
was performed before deployment of self-expanding
metallic stents (Wallstent, Boston Scientific-Schneider,
Minneapolis, MN, USA) (Figs. 1B and 2C). If multiple stents
were used, an overlapping of at least 20 mmwas performed.
After completion iliocavography, the sheath was retrieved
and elastic stockingswere applied. Postoperatively, patients
received subcutaneous low-molecular-weight heparin
therapy (LMWH). The treatment at discharge was initially
fluindion for 6 months; since 2003, patients suffering from
MayeThurner syndrome have been discharged on LMWH for
15 days, and anti-platelet drugs but those with complex
lesions (post-thrombotic and re-canalisation mainly) were
treated by oral anticoagulation for at least 12 months.
Follow-up
Clinical examination and duplex scanning were scheduled
at 1, 3, 6 and 12 months and then annually. VCSS and VDS7
were evaluated before surgery and during the follow-up to
assess clinical results. In case of clinical recurrence of the
symptoms or of restenosis at colour Doppler ultrasonog-
raphy (>50% of in-stent restenosis with inflow obstruction
was considered significant),4,5 transfemoral venography
was performed.Figure 1 Angiographic view of MayeThurner syndrome. A: bef
pathways. B: after stenting.Statistical analysis
Primary, assisted-primary and secondary patency rates
were calculated by using survival analysis with the life-
table method. Continuous variables were analysed by Stu-
dent’s t-test and the Fisher’s exact test for categorical data
when comparing the two groups of patients. The log-rank
test was used to compare cumulative curves. Univariate
analysis of patient characteristics or technical variables
was performed with Fisher’s exact test or chi-square test
(qualitative variables). Any variables found to be significant
in univariate analysis with p< 0.10 were used for multi-
variate analysis and the measure of association was the
adjusted odds ratio (OR). All statistical calculations were
performed with the SPSS software package, version 15.1
(SPSS Software Inc., Chicago, IL, USA).
Results
The results are summarised in Table 2. Procedures were
performed under general anaesthesia in 49 cases, local
anaesthesia in 20 cases and local anaesthesia plus intrave-
nous sedation (midazolam and sufentanyl) in 20 cases. The
access was performed percutaneously in 83 patients (93%)
through the femoral vein in 81 cases, the popliteal vein in one
case and the obturator vein in one case. All seven patients
with bi-ilio-caval lesions had bilateral femoral vein access.
Surgical access was performed in six cases (Table 2). Tech-
nical success rate was 98% (93% for patients needing re-
canalisation) due to re-canalisation failure in two cases (one
hypoplasia and one post-thrombotic lesion with CVF
involvement). In one case external iliac vein re-canalisation
failed, but the common iliac vein was re-canalised by ipsi-
lateral obturator vein access. In another case with bi-ilio-
caval thrombosis, the IVC was re-canalised from the left side
but performing complete re-canalisation of the right
common iliac vein proved to be impossible. The right
ascending lumbar vein which was dilated with multiple
stenoses was stented up to the right renal vein. In all, 121
stents (12e16 mm indiameter and40e90 mm in length)were
used and the mean number of stents for treating the lesionsore stenting: important transversal and ascending collateral
Figure 2 Left femoro-iliac re-canalisation of post-thrombotic lesions. A: after re-canalisation of the external iliac vein.
B: common iliac vein occlusion. C: result after re-canalisation and stenting.
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vein was 91 mm (range: 40e350 mm).
Concomitant procedures were performed in 13 patients:
six left renal vein phlebography with reno-caval pull-back
gradient measurement, three left ovarian vein embolisa-
tion, one IVC clip resection, two left great saphenous vein
high resections (one iterative), one left great saphenous
vein stripping, one left lesser saphenous vein high resec-
tion, one left medial gastrocnemian vein resection and one
skin grafting (the patient had an active ulcer). Five proce-
dural complications occurred: two stent migrations,3 one
superficial femoral artery tear which was treated percuta-
neously by a covered stent (Viabahn, W. L. Gore and
Associates, Flagstaff, AZ, USA) and contrast extravasation
in two cases of re-canalisation.
Neither perioperative death nor pulmonary embolism
occurred. Five postoperative complications occurred: two
thromboses after left iliac vein re-canalisation for post-
thrombotic disease (both with common femoral vein
involvement) treated by successful surgical thrombectomy
in one case, one right hemothorax needing drainage and 2
haematomas at access site (none needed surgical treat-
ment). The median length of hospital stay was 2 days
(range: 1e14 days). Fifty-two patients were dischargedTable 2 Results.
All patients >
N 89 4
Percutaneous access 83 (93%) 3
Technical success 87 (98%) 4
Mean stent number 1.3 1
Mean stented segments 1.3 1
Mean stented vein length 91 mm 7
Stented CFV (%) 8 1
Median length of stay 2 days 3
Median follow-up 38 M 6
Re-thrombosis 5 (6%) 2
Restenosis 6 (7%) 5
Median VDS 1 0
Primary patency 83% at 120 M 7
Assisted-primary patency 89% at 120 M 8
Secondary patency 93% at 120 M 9
VDS: venous disability score; M: months.with oral anticoagulation for at least 6 months and 37 were
discharged with LMWH for 2e3 weeks and anti-platelet
drugs for at least 1 year. Primary and secondary patency
rates were respectively 96% and 97% at 30 days.
Median follow-up was 38 months (1e144) and no patient
was lost. Late complications included one death at
16 months (peritoneal carcinosis caused by colic cancer)
and three late thromboses (all occurred on patients with
history of DVT): one at 1.5 months (successfully treated by
venous thrombectomy, CVF endophlebectomy, iterative
common iliac vein re-canalisation and arteriovenous (AV)
fistula), one at 15 months (treated by successful Palma
procedure) and one at 28 months (successfully treated by
venous thrombectomy, iterative stenting and AV fistula).
Restenosis occurred in six patients after a median delay of
9 months (range, 1e27 months). In five cases (all in patients
with more than 4-year follow-up) restenosis were due to an
underestimation of the length of vein to be stented. In one
case it was due to a very short overlapping between two
stents. All were successfully treated by iterative stenting.
One patient had a Palma procedure 3 months later for
iterative restenosis.
All patients with technical success had clinical
improvement and median VDS decreased from 24 years <4 years p
3 46
7 (86%) 46 (100%) 0.01
1 (95%) 46 (100%) 0.23
1.4 0.303
.1 1.5 0.027
2 mm 106 mm 0.004183
7 0.0593
days 2 days 0.067
8 M 20 M <0.0001
(5%) 3 (7%) 0.99
(12%) 1 (2%) 0.10
1 0.15
8% at 120 M 86% at 42 M 0.239
8% at 120 M 88% at 42 M 0.610
0% at 120 M 97% at 42 M 0.212
Table 3 Univariate analysis.
Variable p value
For primary patency
-history of DVT 0.144
-CFV involvement 0.035
-stented CFV 0.06
For secondary patency
-history of DVT 0.023
-CFV involvement 0.049
-stented CFV 0.325
122 O. Hartung et al.preoperatively to 1 (range: 0e3) at the end of the follow-
up. One patient had healing of his ulcer at 1 month but the
ulcer re-opened when he had thrombosis at 1.5 months; it
healed after re-intervention. All other C6 patients had
healing of their ulcers without recurrence. Of the 45
patients with preoperative venous claudication, all but two
(one had technical failure, one re-thrombosed at day 3 and
was not re-operated) showed improvement, including 31
without residual claudication. Of the 26 patients who
suffered preoperatively from pelvic congestion syndrome,
one had technical failure and another, despite a patent
stent, showed no improvement and 23 had improvement
including 15 who became asymptomatic (one poorly
improved patient had subsequently left renal vein stenting
for nutcracker syndrome).8
Primary, assisted-primary and secondary patency rates
in intention to treat were 89%, 94% and 96%, respectively,
at 1 year and 83%, 89% and 93% at 3 and 10 years (Fig. 3). Of
the 89 patients, 43 were treated more than 4 years ago.
With a median 68 months follow-up (49e144), primary,
assisted-primary and secondary patency rates in intention
to treat were, respectively, 86%, 93% and 95% at 1 year and
78%, 88% and 90% at 3 and 10 years. For the remaining
46 patients (less than 4 years after treatment), median
follow-up was 20 months (range: 1e43 months). Primary,
assisted-primary and secondary patency rates were,
respectively, 93%, 95% and 97% at 1 year and 86%, 88% and
97% at 3 years. Univariate analysis performed on 22 vari-
ables found that CFV involvement was significant for
primary patency although secondary patency was related to
history of DVT and CFV involvement (Table 3). Multivariate
analysis did not indicate any factor associated with
decreased primary or secondary patency but there was
a trend for CFV involvement for primary patency (pZ 0.15,
OR 7.4, 95% CI 0.47e116.7).
Discussion
Since its introduction in the mid-1990s, the concept of the
endovascular approach for ilio-caval obstructive disease
had become popular, thanks to its low invasiveness andFigure 3 Cumulative primary, assisted-primary and secondary pa
of chronic ilio-caval occlusive disease (intention to treat). The curpromising initial results. Short- and mid-term efficiencies
were demonstrated for patients with acute DVT as an
adjunct to thrombolysis9,10 or venous thrombectomy.11,12
Chronic obstructive lesions can schematically be divided
into two groups: non-thrombotic iliac vein lesions (mainly
MayeThurner syndrome) and post-thrombotic lesions. If
both populations are treated for symptomatic and invalid-
ating impact of the obstruction, the extension and the
severity of the lesions are quite different.13 In this report,
in fact, post-thrombotic lesions represent 77% of the
occlusions and all cases of common femoral vein involve-
ment are caused by these lesions. Treatment of C2 patients
can appear excessive but 14 were suffering from invalid-
ating pelvic congestion syndrome and one had varicose
recurrence after left great saphenous vein stripping.
We and others have shown that certain technical rules
have to be followed in order to avoid complications and to
obtain good results.3e5,13e16 Ultrasound-guided puncture is
absolutely needed for patients with lesions involving the
external iliac vein and/or the common femoral vein to
allow access through the femoral vein. In case of limited
lesions, such as the MayeThurner syndrome, access is
performed through the common femoral vein and ultra-
sound guidance is recommended. Treatment requires the
systematic use of large (14e16 mm) and long (6 cm at least)
self-expanding metallic rather than nitinol stents,
protruding into the IVC with large overlapping (at leasttency rates of 89 patients admitted for endovascular treatment
ves are represented as dotted lines when SEM is >10%.
Table 4 Results of the published series of endovascular treatment for chronic ilio-caval occlusive disease.
N Post DVT Technical success FU Late PP Late SP
Nazarian et al.19 56 92% NS 50% at 48 M 75% at 48 M
Blatter and Blatter20 14 85% 15 M 79% at 15 M 79% at 15 M
Razavi et al.*21 17 88% 19 M 80% 87%
O’Sullivan et al.22 20 0% 93.9% at 12 M
Hood and Alexander23 7 NS 100% 19 M 100% 100%
Te Riele et al.*24 9 NS 100% 9 M 78% at 9 M
Raju et al.*25 104 93% 11 M 58% at 24 M 82% at 24 M
Knipp et al.26 58 90% 100% NS 38% at 60 M 73% at 60 M
Oguzkurt et al.27 16 100% 94% NS 72% at 48 M 75% at 48 M
Neglen et al.15 982 47% NS 22 M 67% at 72 M 93% at 72 M
Hartung 89 33% 97% 38 M 83% at 120 M 93% at 120 M
>4 years 43 20% 95% 68 M 78% at 120 M 90% at 120 M
<4 years 46 45% 100% 20 M 86% at 42 M 97% at 42 M
FU: follow-up; PP: primary patency rate; SP: secondary patency rate; M: months; NS: not specified; *: Inferior vena cava involvement in
all patients.
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ultrasound guidance is also recommended5,17 and although
we do not have access to this technology our results are
comparable to those of the literature (Table 3). The use of
this device is quite expensive but its use could have avoided
some cases of restenoses in our early experience due to the
underestimation of lesion length.3
We had previously reported treating 20 patients
suffering from MayeThurner syndrome under local anaes-
thesia,3 but we discontinued because they experienced
very intense back pain. On the other hand, general anaes-
thesia is not necessary in all patients. This gave us a good
reason to develop the use of local anaesthesia plus sedation
(midazolam and sufentanyl). Percutaneous access, ilioca-
vography, catheterism of the lesion and even re-canal-
isation, when needed, can be performed under local
anaesthesia. If the lesion is significant and catheterism (and
re-canalisation) is successful, sedation or general anaes-
thesia is given according to the extent and to the
complexity of the lesions. Re-canalisation is a painless
procedure and can be performed under local anaesthesia,
thus helping to prevent complications (vein perforation is
painful due to the course of the guidewire through the
venous wall into the retroperitoneal space).
One of the main issues is postoperative treatment and
there are no recommendations about it. Neglen18 recom-
mended the use of anti-platelet drugs exclusively. As these
drugs were not shown do be efficient in preventing DVT, we
prefer to use it in association with low-molecular-weight
heparin for 2 weeks for non-thrombotic lesions; however, in
case of re-canalisation or post-thrombotic disease, all
patients were discharged under oral anticoagulation for at
least 1 year. Accordingly, we had only three cases of
re-thrombosis at 12 months, including two within the first
week and all occurred in patients with post-thrombotic
lesions with common femoral vein involvement.
Many authors have published good mid-term results in
term of patency (Table 4)15,19e27 and our long-term results
show that this treatment is durable. Clinical results are also
satisfactory in terms of ulcer healing (100% on six patients in
this report and 58% on 148 limbs for Neglen),15 venous clau-
dication (95% improvement including 68% without residualclaudication) and also pain and swelling, according to Neglen
et al.15 Moreover, 88% of our patients suffering from pelvic
congestion syndrome were improved. Stenting had become
the first-line treatment as stated at the International
Summit of the 5th Pacific Vascular Symposium.5 In our
experience, median delay for restenosis or re-thrombosis
was 8.2 months (range 3 dayse28 months). All thromboses
occurred in patients with post-thrombotic disease or history
of DVT and all restenoses are due to technical errors.
We had to treat 18 patients with lesions extending down
to the inguinal ligament. Of these, eight had stenting and
no thrombosis occurred during the follow-up. On the other
hand, 10 diseased CFV were not stented and three had re-
thrombosis. Even if this is not significant (pZ 0.22) we
think that stenting of diseased CFV should be performed.
According to Neglen et al.,16 stent can be safely positioned
down to the inguinal ligament without the risk of fracture
or effect on patency and the result is dependent upon the
aetiology and the presence or not of an occlusion.
So far, none of our patients experienced contralateral
iliac vein occlusion despite all patients but nine had a left
common iliac vein stent protruding into the IVC. This
complication occurred in 1% of the patients in the study by
Neglen et al.15 It must be emphasised that in cases of left
common iliac stent re-thrombosis, the right common iliac
vein stayed patent with blood flowing through the cells of
the distal part of the stent.
During the last 4 years, we had to treat patients with
more complex lesions (higher preoperative VDS, more
secondary disease, more occlusions, longer length of sten-
ted vein and more segment stented) and this was performed
percutaneously in all patients. Despite this, patency rates
are not different. This is certainly linked with the increase
of our experience that leads us to use ultrasound-guided
puncture in order to facilitate percutaneous venous access
and to deploy longer stents to avoid restenosis.
Conclusion
Stenting has turned out to be the technique of reference
for the treatment of femoro-ilio-caval obstructive lesions
and provides good long-term patency with low complication
124 O. Hartung et al.rates. Despite this, several issues like postoperative
therapy are not resolved and should be evaluated in order
to optimise the results.
Conflict of Interest/Funding
None.
References
1 Plate G, Einarsson E, Ohlin P, Jensen R, Qvarfordt P, Eklof B.
Thrombectomy with temporary arteriovenous fistula: the
treatment of choice in acute iliofemoral venous thrombosis.
J Vasc Surg 1984;1:867e76.
2 Nicolaides AN, Allegra C, Bergan J, Bradbury A, Cairols M,
Carpentier P, et al. Management of chronic venous disorders of
the lower limbs guidelines according to scientific evidence. Int
Angiol 2008;27:1e59.
3 Hartung O, Otero A, Boufi M, Decaridi G, Barthelemy P, Juhan C,
et al. Midterm results of endovascular treatment for symp-
tomatic chronic nonmalignant iliocaval venous occlusive
disease. J Vasc Surg 2005;42:1138e44.
4 NeglenP, RajuS. In-stent recurrent stenosis in stents placed in the
lower extremity venousoutflowtract. JVascSurg2004;39:181e8.
5 Meissner MH, Eklo¨f B, Colerdge Smith P, Dalsing MC,
DePalma RG, Gloviczki P, et al. Secondary chronic venous
disorders. J Vasc Surg 2007;46:68Se83S.
6 Eklo¨f B, Rutherford RB, Bergan JJ, Carpentier PH, Gloviczki P,
Kistner RL, et al. Revision of the CEAP classification for chronic
venous disorders: consensus statement. J Vasc Surg 2004;40:
1248e52.
7 Rutherford RB, Padberg FT, Comerota AJ, Kistner RL,
Meissner MH, Moneta GL. Venous severity scoring. J Vasc Surg
2000;31:1307e12.
8 Hartung O, Grisoli D, Boufi M, Marani I, Hakam Z, Barthelemy P,
et al. Endovascular stenting in the treatment of pelvic vein
congestion caused by nutcracker syndrome: lessons learned
from the first five cases. J Vasc Surg 2005;42:275e80.
9 Mewissen MW, Seabrook GR, Meissner MH, Cynamon J,
Labropoulos N, Haughton SH. Catheter-directed thrombolysis
for lower extremity deep venous thrombosis: report of
a national multicenter registry. Radiology 1999;211:39e49.
10 Comerota AJ, Kagan SA. Catheter-directed thrombolysis for the
treatment of acute iliofemoral deep venous thrombosis. Phle-
bology 2001;15:149e55.
11 Wohlgemuth WA, Weber H, Loeprecht H, Tietze W,
Bohndorf K. PTA and stenting of benign venous stenoses inthe pelvis: long-term results. Cardiovasc Intervent Radiol
2000;23:9e16.
12 Hartung O, Benmiloud F, Barthelemy P, Dubuc M, Boufi M,
Alimi YS. Late results of surgical venous thrombectomy with
iliocaval stenting. J Vasc Surg 2008;47:381e7.
13 Neglen P, Berry MA, Raju S. Endovascular surgery in the treat-
ment of chronic primary and post-thrombotic iliac vein
obstruction. Eur J Vasc Endovasc Surg 2000;20:560e71.
14 Raju S, McAllister S, Neglen P. Recanalization of totally occluded
iliac and adjacent venous segments. J Vasc Surg 2002;36:
903e11.
15 NeglenP,Hollis KC,Olivier J,Raju S. Stentingof thevenousoutflow
in chronic venous disease: long-term stent-related outcome,
clinical, and hemodynamic result. J Vasc Surg 2007;46:979e90.
16 Neglen P, Tackett TP, Raju S. Venous stenting across the
inguinal ligament. J Vasc Surg 2008;48:1255e61.
17 Neglen P, Raju S. Intravascular ultrasound scan evaluation of
the obstructed vein. J Vasc Surg 2002;35:694e700.
18 Raju S, Owen Jr S, Neglen P. The clinical impact of iliac venous
stents in the management of chronic venous insufficiency.
J Vasc Surg 2002;35:8e15.
19 Nazarian GK, Bjarnason H, Dietz Jr CA, Bernadas CA, Hunter DW.
Iliofemoral venous stenoses: effectiveness of treatment with
metallic endovascular stents. Radiology 1996;200:193e9.
20 Bla¨ttler W, Bla¨ttler IK. Relief of obstructive pelvic venous symp-
toms with endoluminal stenting. J Vasc Surg 1999;29:484e8.
21 Razavi MK, Hansch EC, Kee ST, Sze DY, Semba CP, Dake MD.
Chronically occluded inferior venae cavae: endovascular
treatment. Radiology 2000;214:133e8.
22 O’Sullivan GJ, Semba CP, Bittner CA, Kee ST, Razavi MK, Sze DY,
et al. Endovascular management of iliac vein compression
(MayeThurner) syndrome. J Vasc Interv Radiol 2000;11:
823e36.
23 HoodDB,Alexander JQ. Endovascularmanagement of iliofemoral
venous occlusive disease. Surg Clin North Am 2004;84:1381e96.
24 te Riele WW, Overtoom TT, van den Berg JC, van de
Pavoordt ED, de Vries JP. Endovascular recanalization of chronic
long-segment occlusions of the inferior vena cava: midterm
results. J Endovasc Ther 2006;13:249e53.
25 Raju S, Hollins K, Neglen P. Obstructive lesions of the inferior
vena cava: clinical features and endovenous treatment. J Vasc
Surg 2006;44:820e7.
26 Knipp BS, Ferguson E, Williams DM, Dasika N, Cwikiel W,
Henke PK, et al. Factors associated with outcome after inter-
ventional treatment of symptomatic iliac vein compression
syndrome. J Vasc Surg 2007;46:743e9.
27 Oguzkurt L, Tercan F, Ozkan U, Gulcan O. Iliac vein compression
syndrome: outcome of endovascular treatment with long-term
follow-up. Eur J Radiol 2008;68:487e92.
